Decoding Interstitial Lung Disease : Identifying and managing Progressive Phenotypes Imre Noth, MD 7/9/19
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.
Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF).
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Acute exacerbations of idiopathic pulmonary fibrosis.
Patient experiences with pulmonary fibrosis.
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.
Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia.
Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality.
Idiopathic pulmonary fibrosis.
An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses.
Acute Exacerbation in Interstitial Lung Disease.
Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential.
Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis.